Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.

Journal for immunotherapy of cancer·2024
Same author

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.

Blood cancer journal·2024
Same author

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case report.

EJHaem·2022
Same author

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.

Cancers·2021
Same author

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Annals of hematology·2018
Same author

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

Hematological oncology·2015
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 22, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

マルチプルミエロマ (多発性ミエロマ) とは

Marc S Raab1, Klaus Podar, Iris Breitkreutz

  • 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Lancet (London, England)
|June 23, 2009
PubMed
まとめ
この要約は機械生成です。

多発性骨髄腫は,悪性プラズマ細胞と骨髄の微小環境を含む. 両方を標的とする新型の治療法は,多発性骨髄腫および他の癌の患者のアウトカムを改善します.

さらに関連する動画

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

関連する実験動画

Last Updated: Jun 22, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

科学分野:

  • 腫瘍学 腫瘍学
  • 血液学 ヘマトロジ

背景:

  • 多発性骨髄腫は,悪性プラズマ細胞の癌である.
  • 骨髄の微小環境は,骨髄腫の発達と進行において重要な役割を果たします.

研究 の 目的:

  • 多発性骨髄腫の病原性における骨髄マイクロ環境の役割を検討する.
  • 骨髄腫細胞とそのマイクロ環境の両方を標的とした新しい治療薬の影響を強調する.

主な方法:

  • 多発性骨髄腫とその治療に関する既存の文献のレビュー.
  • タリドマイド,ボルテゾミブ,レーナリドマイドなどの薬剤の作用機構の分析.

主要な成果:

  • 骨髄のマイクロ環境と骨髄腫細胞をターゲットにすることで,治療効果が向上します.
  • タリドマイド,ボルテゾミブ,レーナリドマイドなどの薬剤は,有意な効果を示しています.
  • これらの薬剤は,全体的な応答,応答の持続時間,進行性のない生存率,および全体的な生存率を改善します.

結論:

  • 骨髄のマイクロ環境は,多発性骨髄腫における重要な治療目標である.
  • これらの新薬をファーストラインの治療計画に組み込むことは,患者にとって改善された結果をもたらします.
  • この治療アプローチは,他の血液学的悪性腫瘍や固体腫瘍にも有望である.